Neptune, the Only Krill Oil Manufacturer Certified as "Friend of the Sea"
2012年5月22日 - 4:00PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX:NTB) is proud to announce that it has been
certified as a "Friend of the Sea" and that it is the only krill
oil manufacturer to obtain that certification.
Neptune engaged in a certification process with Friends of the
Sea (''FOS''), an internationally recognized organization which
verifies the sustainable origin of marine products. FOS has been
selected by Omega-3 producers worldwide as the most independent and
reliable sustainability certification. The eco-label also provides
an effective way to communicate environmental performance to their
customers.
Neptune successfully obtained FOS certification by complying
with strict krill sustainability criteria which ensure:
- The stock is not overfished
- The fishery is in compliance with the management measures
- Does not have bycatch of endangered species
- Does not have an adverse impact on the ecosystem or seabed
- Social accountability
- Gradual reduction of carbon footprint
This certification can also be extended to distributors who can
successfully substantiate that Neptune is their sole krill oil
provider. Once audited, it will allow them to include the FOS logo
on their packaging and marketing material. The FOS claim is very
straight forward and easily understood by consumers compared to
other sustainability certifications.
In conjunction, with the NSF accreditation obtained in 2011,
Neptune has ensured an environmentally responsible business
approach from sourcing of raw material to commercialization.
Mr. Paolo Bray, President of the FOS organization, recently won
the UK People & Environment Achievement Business Awards (PEABs)
2012. The PEABs recognize green initiatives that are good for
business as well as the planet. The award judges included figures
from the WWF, Time News Paper as well as PricewaterhouseCoopers
Sustainability and Climate Change team. He commented, "So far
Friends of the Sea has only approved 30 fisheries and deemed 8 as
non-sustainable. We attribute that to our stricter standard for
certifying fisheries, which has satisfied many environmental
bodies." FOS has certified companies in the like of
GlaxoSmithKline, BASF-Cognis and Nordic Naturals.
"We are proud to be the only krill oil certified FOS and be
partner with an exceptional figure representing a strong and
strategic organization with the environment's well-being as its
primary mission," added Wael Massrieh, Vice-President, Scientific
Affairs.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 30
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX) accepts responsibility for the adequacy or accuracy of this
release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain
and forward-looking. The forward-looking statements contained
herein are also subject generally to other risks and uncertainties
that are described from time to time in the Company's reports filed
with the Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024